Pharming Group inks US marketing deal for RUCONEST®
Ticker: PHAR · Form: 6-K · Filed: Sep 26, 2024 · CIK: 1828316
| Field | Detail |
|---|---|
| Company | Pharming Group N.V. (PHAR) |
| Form Type | 6-K |
| Filed Date | Sep 26, 2024 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: marketing-agreement, distribution, pharmaceuticals
TL;DR
Pharming inks US marketing deal for RUCONEST® with Ascendia Pharmaceuticals.
AI Summary
Pharming Group N.V. announced on September 26, 2024, that its subsidiary, Pharming Healthcare Inc., has entered into a marketing and distribution agreement with Ascendia Pharmaceuticals LLC for the drug RUCONEST® in the United States. This agreement is effective immediately and aims to expand the reach of RUCONEST® within the US market.
Why It Matters
This agreement allows Pharming to leverage Ascendia's expertise to increase RUCONEST®'s market penetration in the US, potentially boosting sales and patient access.
Risk Assessment
Risk Level: low — The filing is a routine announcement of a marketing agreement, not indicating significant new risks.
Key Players & Entities
- Pharming Group N.V. (company) — Registrant
- Pharming Healthcare Inc. (company) — Subsidiary of Pharming Group N.V.
- Ascendia Pharmaceuticals LLC (company) — Marketing and Distribution Partner
- RUCONEST® (product) — Drug being marketed
- September 26, 2024 (date) — Date of announcement
FAQ
What is the specific nature of the agreement between Pharming Healthcare Inc. and Ascendia Pharmaceuticals LLC?
Pharming Healthcare Inc. has entered into a marketing and distribution agreement with Ascendia Pharmaceuticals LLC for RUCONEST® in the United States.
When was this agreement announced?
The agreement was announced on September 26, 2024.
Which subsidiary of Pharming Group N.V. is involved in this agreement?
Pharming Healthcare Inc. is the subsidiary involved in the agreement.
What product is the subject of this marketing and distribution agreement?
The product is RUCONEST®.
In which geographical region will Ascendia Pharmaceuticals LLC market and distribute RUCONEST®?
Ascendia Pharmaceuticals LLC will market and distribute RUCONEST® in the United States.
Filing Stats: 1,444 words · 6 min read · ~5 pages · Grade level 11.6 · Accepted 2024-09-26 06:02:53
Filing Documents
- pharmingannouncesmarketing.htm (6-K) — 36KB
- logo_greyxoriginalx.jpg (GRAPHIC) — 112KB
- logo_pharmingxoriginal.jpg (GRAPHIC) — 18KB
- 0001828316-24-000031.txt ( ) — 204KB
Forward-looking Statements
Forward-looking Statements This press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management's current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as "aim", "ambition", anticipate'', believe'', could'', estimate'', expect'', goals'', intend'', may'', "milestones", objectives'', outlook'', plan'', probably'', project'', risks'', "schedule", seek'', should'', target'', will'' and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates, Pharming's clinical and commercial prospects, and Pharming's expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming's clinical trials and ramifications for the cost thereof and clinical, scientific, regulatory, commercial, competitive and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming's 2023 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to